We don't really know what each therapy is doing inside the tumor.
Glioblastoma, the most aggressive of adult brain cancers, has resisted decades of medical effort — survival measured in months, not years, and treatment decisions made largely in the dark. Now, a coalition of five major cancer centers, backed by eight million dollars in Department of Defense funding, is attempting something more ambitious than a new drug: a new way of seeing the disease as it unfolds. The McCain/Bayh Glioblastoma Consortium is pursuing personalized, real-time understanding of how individual tumors respond to treatment — a shift from medicine that reacts to medicine that adapts.
- Glioblastoma kills most patients within two years, and decades of research have moved the survival needle only a few months — the urgency is not hypothetical.
- The central problem is invisibility: once treatment begins, doctors lose meaningful sight of what is happening inside the tumor, leaving critical decisions to guesswork and imprecise imaging.
- A five-institution consortium funded by the DoD is now attacking the disease simultaneously from immunotherapy, genomics, liquid biopsy, and microbiome angles — coordinated rather than isolated.
- UCLA's flagship effort combines imaging, tissue analysis, and blood tests to build a continuous, dynamic portrait of each patient's tumor, aiming to replace population-level guesses with individual-level data.
- If biomarkers can be identified that predict which patients respond to which therapies, the result could be faster treatment pivots, fewer invasive procedures, and a fundamentally more adaptive standard of care.
Glioblastoma is the most common malignant brain tumor in adults, and it is merciless. Despite decades of research, median survival has improved only modestly — from roughly twelve months to somewhere between fourteen and eighteen. The disease remains one of oncology's most resistant problems, and a central reason is becoming clearer: once treatment begins, doctors lose meaningful visibility into what is actually happening inside the tumor.
That visibility problem is the animating challenge behind the McCain/Bayh Glioblastoma Consortium, a new multi-institution initiative funded by eight million dollars from the U.S. Department of Defense. The consortium unites UCLA, Duke University, UC San Francisco, Memorial Sloan Kettering, and MD Anderson — each approaching the disease from a different direction, all working toward a shared goal of personalized, real-time treatment.
At UCLA, Timothy Cloughesy leads the consortium's flagship project. Tumor tissue is typically collected at diagnosis and perhaps again at recurrence, leaving physicians to rely on imaging scans that often fail to capture the true dynamics of disease progression. His team is working to close that gap by combining advanced imaging, tumor tissue analysis, and blood tests drawn throughout treatment — building what he describes as a more dynamic picture of how each patient's disease is evolving. Colleague David Nathanson put the core mystery plainly: some patients respond dramatically to a given therapy while others see almost no benefit, and medicine still does not fully understand why.
The other consortium members address complementary dimensions. Duke is testing immunotherapy combinations and trying to identify which patients will respond. UCSF is mapping genetic variation within individual tumors to understand why some regions resist treatment. Memorial Sloan Kettering is studying tumor DNA in cerebrospinal fluid as a less invasive monitoring tool. MD Anderson is investigating whether the body's microbiome shapes immunotherapy response.
Together, the effort represents a shift in ambition — not just finding new drugs, but building the capacity to adapt treatment in real time based on actual data from individual patients. For families facing a diagnosis that still carries a median survival under two years, the promise is not only better therapies, but faster answers.
Glioblastoma kills quickly and quietly. It is the most common malignant brain tumor in adults, and it is relentless. Most patients diagnosed with it will be dead within two years. Despite decades of research, the medical establishment has managed only modest gains—survival times have crept from around twelve to fourteen months up to fourteen to eighteen months. The disease remains one of oncology's most stubborn problems, and the reasons why are becoming clearer: doctors simply cannot see what is happening inside the tumor once treatment begins.
This visibility problem sits at the heart of a new research initiative now underway across five major cancer centers, funded by the U.S. Department of Defense with eight million dollars in grants. The McCain/Bayh Glioblastoma Consortium brings together teams from UCLA, Duke University, the University of California San Francisco, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. Each institution is attacking the disease from a different angle, but they share a common goal: to move beyond the crude tools doctors currently rely on and develop a personalized approach to treatment that can adapt in real time as the disease evolves.
At UCLA Health's Jonsson Comprehensive Cancer Center, Timothy Cloughesy, director of the Neuro-Oncology Program, leads the consortium's flagship effort. The problem he and his team are trying to solve is straightforward but profound. Tumor tissue is typically collected once, at the moment of diagnosis. If the cancer returns, surgeons may collect another sample. In the months or years between these two moments, physicians are flying blind, relying almost entirely on imaging scans that are difficult to interpret and often fail to capture the true dynamics of what is happening. "We don't really know what each therapy is doing inside the tumor," Cloughesy said. That gap between what doctors administer and what they can actually observe is where treatment failures hide.
The UCLA project aims to close that gap by combining three streams of data: advanced brain imaging, detailed analysis of tumor tissue samples, and blood tests collected throughout the course of treatment. By tracking how tumors and the immune system change over time, researchers hope to build what Cloughesy calls a more dynamic picture of the disease. The goal is not just to know whether a therapy works, but to understand how it works and, crucially, why it works for some patients and fails for others. David Nathanson, a professor of molecular and medical pharmacology at UCLA's David Geffen School of Medicine, noted that clinicians often observe a striking pattern: some patients respond dramatically to a given treatment while others show almost no benefit. "We still don't fully understand why," he said. "This effort is about learning from those differences so we can make better decisions for patients as the disease evolves."
If researchers can identify biological patterns—biomarkers—that distinguish patients likely to respond well to specific treatments, the implications could be substantial. Doctors could match therapies or clinical trials to the patients most likely to benefit from them. The need for invasive procedures could diminish. Most importantly, treatment decisions could be made in real time, based on actual data about how an individual's tumor is responding, rather than on population-level statistics or educated guesses. The shift would be from reactive to adaptive medicine.
The broader consortium distributes the work across complementary projects. Duke University is testing combinations of immunotherapy drugs to understand how to activate the immune system against glioblastoma and identify which patients will respond. UC San Francisco is mapping the genetic makeup of tumors across different regions within the same patient, trying to understand why some areas respond to treatment while others resist it. Memorial Sloan Kettering is studying tumor DNA in cerebrospinal fluid as a less invasive way to monitor changes and treatment response. MD Anderson is investigating whether the microbiome—the community of microorganisms in the body—influences how well patients respond to immunotherapy. Each piece addresses a different dimension of the puzzle.
Cloughesy frames the work in terms of integration. "Each of us is looking at a different piece of the puzzle," he said. "The hope is that each of these pieces eventually will come together and we get this holistic understanding and insight of what's going on." For patients and families, the shift could mean more than new drugs. It could mean faster answers. It could mean the ability to adapt treatment based on real data rather than waiting months to see whether a chosen therapy is working. It could mean that every piece of information gathered from a patient's treatment becomes meaningful not just for that individual, but for the next patient facing the same disease.
Citações Notáveis
We've moved from maybe 12 to 14 months of survival to something closer to 14 to 18 months. That's not the kind of progress we're looking for.— Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA
We often see a subset of patients who do very well, while others show little to no benefit, and we still don't fully understand why.— David Nathanson, professor of molecular and medical pharmacology at UCLA
A Conversa do Hearth Outra perspectiva sobre a história
Why has glioblastoma survival improved so little, even with all the research money and attention it's received?
The core problem is that doctors are working with incomplete information. They see the tumor at diagnosis, maybe again if it comes back, and in between they're interpreting imaging scans that don't tell them what's actually happening at the cellular level. It's like trying to manage a business by looking at quarterly reports while the market is moving daily.
So the new approach is to collect data continuously throughout treatment?
Exactly. They're combining imaging, tissue samples, and blood tests over time to build a real picture of how the tumor is responding. That lets them see patterns—which patients respond to which treatments, and why some people benefit while others don't.
And those patterns are what they're calling biomarkers?
Right. If you can identify a biological signature that predicts who will respond to a specific therapy, you can match patients to treatments that are actually likely to work for them, rather than cycling through options blindly.
Does that reduce the number of surgeries patients have to endure?
Potentially, yes. If you can monitor tumor changes through blood tests and imaging instead of going back in for tissue samples, that's fewer invasive procedures. And it means doctors can make adjustments faster, based on real data about what's happening.
What makes this consortium different from previous glioblastoma research efforts?
The scale and coordination. Five major centers, each tackling a different piece—immunotherapy, genetics, microbiome, cerebrospinal fluid monitoring. They're designed to feed into each other, to build a complete picture rather than isolated findings.
And the timeline? When might patients actually see these benefits?
That's the real question. The research is just beginning. But the structure is designed to accelerate answers—to move from the current model of waiting months to see if a treatment worked to a model where you know in real time.